Basis Medicine Announces Govt Management Changeover | Enterprise & Finance

CAMBRIDGE, Mass.–(Company WIRE)–Jan 19, 2021–

Basis Drugs, Inc. now announced the transition of Cindy Perettie, Chief Govt Officer, to Roche Diagnostics to lead the Molecular Lab Alternatives company headquartered in Pleasanton, California effective April 6, 2021.

Ms. Perettie was appointed CEO of Foundation Medicine in February 2019. Beneath her leadership, Foundation Medication has expanded its leading situation in in depth genomic most cancers testing and in offering molecular insights for clinicians and the biopharma sector to rework most cancers treatment. Throughout her tenure, Foundation Medication acquired Food and drug administration acceptance for its FoundationOne ® Liquid CDx companion diagnostic examination, which analyzes the premier genomic area of any Fda-authorised in depth liquid biopsy examination, signed a partnership with Natera, Inc for the joint improvement and commercialization of personalised circulating tumor DNA monitoring assays, acquired Lexent Bio to more speed up exploration and advancement in early cancer diagnostics, and proven world-wide partnerships with suppliers and the biopharma industry to progress precision medication and increase individual care and results in oncology.

Prior to taking the helm at Basis Drugs, Ms. Perettie served in several management roles with Roche and Genentech, most not long ago as senior vice president with product method accountability for the global oncology portfolio. Before signing up for the Roche Team, she led global portfolio management for IVAX Prescription drugs, was the President of International Improvement Improvements for the Sarah Cannon Research Institute dependent in Nashville, Tennessee, and served as Director of World Plan Administration at Élan Corporation based in the United Kingdom. Ms. Perettie retains a master’s degree of advertising and finance from St. Mary’s School of California and obtained her bachelor’s degree in biology, with a minor in chemistry, from Condition University of New York School at Potsdam.

“Cindy’s company impact and leadership excellence are evident in what she and her team have attained during her almost two-calendar year tenure. Coupled with her extensive scientific and professional experience, Cindy has expanded Foundation Medicine’s field-primary posture in providing molecular insights to advance cancer investigation and clinical treatment,” said Severin Schwan, CEO, Roche Group. “She will be pivotal for the even further transformation of our small business and the up coming technology of Diagnostics options. My sincere many thanks to Cindy and her staff for all that they have previously contributed for the advantage of people and health care systems.”

Brian Alexander, M.D., M.P.H., Basis Medicine’s Senior Vice President and Chief Medical Officer, will grow to be the interim chief for the corporation right after April 6 and be certain a smooth transition right up until a successor is in spot.

About Foundation Medicine

Foundation Drugs is a molecular details business dedicated to a transformation in most cancers treatment in which procedure is knowledgeable by a deep comprehending of the genomic adjustments that contribute to each patient’s one of a kind most cancers. The enterprise gives a entire suite of comprehensive genomic profiling assays to determine the molecular alterations in a patient’s most cancers and match them with pertinent specific therapies, immunotherapies and scientific trials. Foundation Medicine’s molecular information and facts platform aims to make improvements to day-to-working day care for people by serving the needs of clinicians, academic scientists and drug builders to enable progress the science of molecular medicine in cancer. For much more info, remember to visit or observe Basis Medication on Twitter (@FoundationATCG ).

Basis Medicine ® and FoundationOne ® are registered logos of Basis Medicine, Inc.

Resource: Basis Medicine



Resource: Basis Medicine

Copyright Small business Wire 2021.

PUB: 01/19/2021 07:00 AM/DISC: 01/19/2021 07:00 AM

Copyright Company Wire 2021.